Homocysteine and Clinical Outcomes in Intracerebral Hemorrhage Patients: Results from the China Stroke Center Alliance
Dandan Wang,Zhentang Cao,Zixiao Li,Hongqiu Gu,Qi Zhou,Xingquan Zhao,Yongjun Wang
DOI: https://doi.org/10.2147/NDT.S391618
IF: 2.989
2022-12-07
Neuropsychiatric Disease and Treatment
Abstract:Dandan Wang, 1, 2 Zhentang Cao, 3 Zixiao Li, 1, 2, 4 Hongqiu Gu, 2 Qi Zhou, 2 Xingquan Zhao, 1, 2, 4 Yongjun Wang 1, 2, 4 1 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China; 2 China National Clinical Research Center for Neurological Diseases, Beijing, People's Republic of China; 3 Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China; 4 Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, People's Republic of China Correspondence: Xingquan Zhao; Yongjun Wang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Fengtai District, Beijing, 100070, People's Republic of China, Tel +86-010-59978891 ; +86-010-59978330, Email ; Objective: Elevated homocysteine (Hcy) levels play a detrimental role in ischemic stroke. Acute spontaneous intracerebral hemorrhage (ICH) accounts for nearly 25% of all stroke cases. However, the influence of Hcy levels and ICH severity on clinical outcomes is unclear. Participants and Study Location: Data were obtained from 85,705 ICH patients enrolled in the China Stroke Center Alliance (CSCA) study, a national, hospital-based, multicenter, voluntary, quality assessment and improvement initiative performed in China. Patients were divided into high and normal Hcy groups according to their Hcy levels observed at admission. Outcome Measures: The outcome indices included severe ICH, in-hospital mortality, and a poor functional outcome at discharge. Multivariable logistic regression was used to analyze the association of different Hcy levels with outcomes. Results: The final analysis included 55,793 ICH patients. High homocysteine (HHcy) levels had higher adjusted odds ratios for severe ICH (OR 1.09, 95% CI 1.01– 1.10, P < 0.0001) and a poor functional outcome at discharge (OR 1.06, 95% CI 1.01– 1.10, P =0.0100) compared with normal Hcy levels. There was no significant difference between HHcy and in-hospital mortality. In the subgroup analysis, stratified by sex and history of hypertension, significant interactions were observed between HHcy and severe ICH ( P for interactions was 0.0138 and 0.0120, respectively). HHcy levels exhibited greater associations for severe ICH in female patients (OR 1.07, 95% CI 1.02– 1.12) and patients without hypertension (OR 1.20, 95% CI 1.09– 1.33). Conclusion: An elevated Hcy level exhibited significant association with severe ICH on admission and a poor functional outcome at discharge. The relationship between HHcy and ICH severity on admission was more robust in female patients and patients without hypertension. Hcy might be a valuable biomarker for ICH patients to predict severity at onset and functional outcome at discharge. Keywords: intracerebral hemorrhage, homocysteine, stroke severity, outcome Homocysteine (Hcy) is a sulfhydryl-containing amino acid that occurs as an intermediate component in methionine metabolism. 1 When the pathway is impaired, Hcy levels increase. According to previous studies, 2–5 elevated Hcy levels exert detrimental effects and elevate the mortality rates on ischemic stroke and cardiovascular diseases. A meta-analysis reported that vitamin B supplementations that reduced Hcy prevented the combined risk of stroke, myocardial infarction, and vascular death among stroke patients. 6 However, many of the previous researches have been limited to ischemic stroke, and few published studies are available concerning hemorrhagic stroke. Globally, acute spontaneous intracerebral hemorrhage (ICH) accounts for approximately 25% of all stroke cases. 7 The subsequent serious complications, morbidity, and mortality associated with ICH account for approximately half of the disability-adjusted life-years lost due to stroke. 7,8 Thus, ICH exacts an immense burden on families and society. Presently, there is no specific treatment available for ICH. Therefore, it is imperative to explore more effective intervention targets to reduce the fatality and disability rates associated with ICH. Several studies have reported that high Hcy (HHcy) is an independent risk factor for hemorrhagic stroke due to the promotion of plaque rupture. 9 However, it is unclear whether the Hcy level observed at admission is associated with ICH severity and clinical outcomes. Because Hcy is a modifiable risk factor that can be prevented and treated by vi -Abstract Truncated-
psychiatry,clinical neurology